Summary
Factor VIII inhibitors in mild haemophilia are uncommon and the management of such
patients is controversial. The development of a persistently high responding F VIII
inhibitor in a mild haemophiliac is reported and the behaviour of the inhibitor discussed
in the context of the various therapeutic regimes employed for symptomatic management.
When inhibitor titres were low, endogenous F VIII stimulation, by DDAVP, was less
immunogenic than the administration of exogenous F VIII concentrates. This inhibitor
displayed characteristics of an autoantibody, and was characterised as an immunoglobulin
of IgG subtype.
Keywords
F VIII inhibitors - Activated prothrombin complex concentrates - Porcine F VIII -
DDAVP
